Zepbound No Longer in Shortage: What This Means for Compounded Tirzepatide

Zepbound No Longer in Shortage: What This Means for Compounded Tirzepatide

In a significant development for patients relying on weight loss and diabetes medications, the U.S. Food and Drug Administration (FDA) has announced that the shortage of Zepbound, a drug containing the active ingredient tirzepatide, is officially over. This marks the end of a challenging period that began in December 2022, during which patients and healthcare providers faced difficulties in accessing this crucial medication.

The Impact on Compounded Tirzepatide

During the shortage, compounding pharmacies stepped in to fill the gap by producing off-brand versions of tirzepatide. These compounded medications provided an affordable and accessible alternative for many patients, especially those who struggled to obtain the brand-name drug. However, with the FDA’s recent announcement, the landscape is set to change.

The FDA has mandated that all compounding pharmacies cease the production of compounded tirzepatide by March 2025. This decision is based on the improved availability of the brand-name medication, ensuring that patients receive FDA-approved drugs that have undergone rigorous safety and efficacy reviews4.

What Patients Need to Know

For patients who have been using compounded tirzepatide, this transition may require some adjustments. Here are a few key points to consider:

1. 1. Plan Ahead: Patients should discuss alternative options well before the March 2025 deadline. Assuming you don’t have coverage for the brand-name medications your options are to:
      • • Pay out-of-pocket for brand-name Zepbound (cost is around $500 monthly)
        • Transition to compounded semaglutide, knowing that Wegovy/semaglutide will also most likely eventually be removed from the shortage list.
        • Transition to a more affordable, oral medication.
        • Consider a more permanent solution like a gastric sleeve, which can be a lot cheaper in the long-run.
   2. Financial Considerations: Compounded versions were often more affordable than brand-name medications. Patients may need to explore manufacturer discounts, coupons, patient assistance programs, or alternative medication options to manage the cost.
   3. Stay Informed: Keeping an eye on reputable news sources and FDA announcements is crucial. Guidelines could shift again in the event of another shortage, potentially reopening the door for compounding.

Conclusion

Although on the surface it may sound like a positive development, the resolution of the Zepbound shortage for many patients will be detrimental as it eliminates the use of more affordable compounded tirzepatide option. The availability of compounded semaglutide will eventually share this same. As all studies show that the majority will regain their lost weight after stopping a GLP-1, patients need to take this into consideration when looking at their best long-term option for weight loss.

Dr. Trace Curry is the Medical Director of JourneyLite and has been a weight loss expert for over 20 years in the Midwest. JourneyLite offers powerful, minimally invasive surgical options such as SADI-S, gastric bypass, and gastric sleeve. He also has a team of medical weight loss experts who offer GLP-1 medications, oral weight loss medications. If you’re not interested in surgery or meds, they also offer the Spatz-3 Adjustable Gastric Balloon. If you need to lose weight, JourneyLite can help!